60 Degrees Pharma

Name

60 Degrees Pharma

Legal name

60 Degrees Pharmaceuticals, Inc.

Website

https://60degreespharma.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Infectious disease pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

akta.pro secondary industries

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), In Vivo Pharmacology (Efficacy/PD Models) (HLAGAFAA)

Keywords

• Malaria prevention drugs
• Infectious disease therapeutics
• Tafenoquine pharmaceuticals
• Antimalarial prophylaxis
• Tropical disease medicines

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Pharmaceutical Product Sales: Revenue from sales of FDA-approved ARAKODA (tafenoquine) for malaria prevention in the U.S. and Australia markets. Product revenues grew 65% to $1.005 million in 2025.
2. Capital Raises: Public offerings and private placements to fund operations, R&D, and commercialization activities. The company raised $5 million gross in July 2025, $4 million in September 2024, and $2.4 million in January 2024.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Core offering

60 Degrees Pharmaceuticals develops and commercializes prescription medicines for the treatment and prevention of infectious diseases. Its lead commercial product is ARAKODA (tafenoquine), an FDA-approved once-weekly malaria prophylaxis tablet marketed in the U.S. and Australia (as KODATEF). The pipeline extends tafenoquine to chronic babesiosis and fungal infections, celgosivir to dengue and respiratory viruses, and a castanospermine-based non-prescription dietary supplement under exclusive license from Florida State University.

Product overview

60 Degrees Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing medicines for infectious diseases. The company's lead product is ARAKODA (tafenoquine), an FDA-approved once-weekly malaria prevention medication commercially available in the U.S. and Australia. The pipeline includes tafenoquine for additional indications (babesiosis treatment, fungal diseases), celgosivir for dengue and respiratory viruses, and Australian Chestnut Extract as a dietary supplement. The company operates through global partnerships for distribution and clinical development.

Differentiator

Problem solved

Functional benefit

Brands

• ARAKODA: FDA-approved tafenoquine tablets for malaria prevention
• KODATEF

Products and services

• ARAKODA (tafenoquine) FDA-approved once-weekly prescription medication for malaria prevention in U.S. travelers visiting endemic regions, featuring a 16-day half-life and a required three-day loading phase before travel.
• KODATEF (tafenoquine) Tafenoquine product approved by the Australian Therapeutic Goods Administration for malaria prevention, distributed exclusively in Australia through Biocelect.
• Tafenoquine for babesiosis treatment Pipeline indication evaluating tafenoquine in Phase 2 proof-of-concept clinical trials for treatment of babesiosis, a tick-borne parasitic disease for which no FDA-approved treatment exists.
• Celgosivir Host-targeted glucosidase inhibitor being developed for treatment of dengue fever and respiratory viruses including RSV and COVID-19, repositioned from prior HIV and hepatitis C programs.
• Australian Chestnut Extract (Castanospermine) Dietary Supplement Botanical supplement candidate for non-prescription use based on castanospermine extracted from Australian Chestnut seeds, under exclusive license from Florida State University.

Quantifiable outcome

• Approximately 100% cure rate in immunosuppressed patients with relapsing babesiosis when weekly tafenoquine is added to standard atovaquone-containing combination regimens
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Florida State UniversitycoreStrategic or Co-development Partner · 11 June 2026Exclusive patent licensing agreement to develop large-scale extraction techniques for castanospermine from Australian Chestnut seeds for non-prescription dietary supplement use. Company plans to meet with FDA on July 1, 2026 regarding NDIN filing.
• GoodRxcoreGTM or Marketing Partner · 2 February 2026Partnership to improve affordability and accessibility of ARAKODA, allowing eligible patients to save up to 30% at over 70,000 pharmacies nationwide. Discounted pricing available starting February 2, 2026.
• Runway HealthcoreGTM or Marketing Partner · 22 January 2026Telehealth partnership to expand access to ARAKODA through direct-to-patient platform launching April 2, 2026. Enables eligible travelers to receive physician-led online consultations and home delivery of prescribed medication matched to their travel itinerary.
• North Carolina State UniversityminorStrategic or Co-development Partner · 29 December 2025Research collaboration on Babesia infection in chronic fatigue patients. Study found 24% of 50 patients with chronic fatigue tested positive for Babesia. Published in Pathogens journal and funded by 60 Degrees Pharmaceuticals.
• Mount Sinai Icahn School of MedicinecoreStrategic or Co-development Partner · 21 November 2025Clinical trial site for B-FREE Chronic Babesiosis Study evaluating tafenoquine efficacy and safety in treating chronic babesiosis patients with severe fatigue.
• Walter Reed Army Institute of Research / U.S. ArmycoreStrategic or Co-development Partner · 9 August 2018Licensed technology from U.S. Army for tafenoquine development. US Army-supported $18+ million development program. Cooperative research and development agreement secured commercialization rights for malaria prophylaxis.
• Duke-NUS Medical School / SingHealthminorStrategic or Co-development Partner · 30 July 2014Exclusive licensing deal to further develop celgosivir for dengue fever. Phase I clinical study demonstrated safety in dengue patients with trend toward faster NS1 clearance.
• BiocelectcoreChannel Partner/ Reseller/ DistributorAustralian distribution partner for ARAKODA/KODATEF. Level 4, 143 Macquarie St, Sydney NSW 2000, Australia. Company commercially launched KODATEF in Australia in September 2018.
• Scandinavian Biopharma Distribution ABminorChannel Partner/ Reseller/ DistributorInternational operations partner in Scandinavia. Located at Industrivägen 1 171 48 Solna, Sweden.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bavarian Nordic: Bavarian Nordic is a specialty infectious disease vaccine company (JYNNEOS for mpox/smallpox, tick-borne encephalitis vaccine) that built its business on licensed government/military-originated technologies. Mirrors 60P's strategy of licensing military-developed assets (tafenoquine from Walter Reed) for commercial development in infectious diseases.
• BioCryst Pharmaceuticals: BioCryst markets Krintafel (tafenoquine) for radical cure of P. vivax malaria, using the same tafenoquine molecule that 60P markets as ARAKODA for prevention. Both companies are small specialty infectious disease pharma firms developing tafenoquine-based products, making them the closest direct peer despite targeting different malaria indications.
• Atea Pharmaceuticals: Atea Pharmaceuticals is a small clinical-stage infectious disease company developing antivirals, including for dengue and respiratory viruses. Overlaps with 60P's celgosivir program for dengue and respiratory viruses, and shares the small-cap infectious disease specialty pharma profile.
• ANI Pharmaceuticals: ANI Pharmaceuticals is a small specialty pharmaceutical company focused on niche generics, branded specialty, and rare disease products. It offers a comparable profile to 60P as a small public specialty pharma with a focused portfolio, government channel exposure, and ongoing pipeline expansion through in-licensing.
• SIGA Technologies: SIGA Technologies is a small specialty infectious disease pharmaceutical company that developed TPOXX (tecovirimat) for smallpox under FDA Priority Review and government stockpiling contracts. It mirrors 60P's profile as a niche infectious disease pharma with a single FDA-approved drug and government/military channel exposure.
• Citius Pharmaceuticals: Citius Pharmaceuticals is a small specialty pharma developing and commercializing critical care and infectious disease products, listed on Nasdaq. It shares the micro-cap, single-product or narrow-pipeline profile, late-stage clinical pipeline, and ongoing capital-raise cadence typical of small specialty infectious disease pharma.

Broad incumbents

• GSK (GlaxoSmithKline): GSK markets Malarone (atovaquone/proguanil), the leading daily-dose malaria prophylaxis, and the Mosquirix malaria vaccine. GSK competes directly with ARAKODA in malaria prevention via its widely-used daily alternative, making it the most relevant broad incumbent competitor despite vastly greater scale.
• Emergent BioSolutions: Emergent BioSolutions is a broader infectious disease and public health preparedness company selling vaccines, therapeutics, and devices to government and commercial customers. Comparable to 60P through its infectious disease focus, government/military channel, and biologics/small molecule franchise, though at significantly larger scale.
• Sanofi: Sanofi Pasteur is a major vaccine and tropical disease pharmaceutical manufacturer, with malaria programs, traveler vaccines, and a global public health infectious disease franchise. It represents the broad incumbent in tropical/infectious disease pharma against which 60P's ARAKODA competes for traveler and institutional segments.
• Lupin Pharmaceuticals: Lupin manufactures and distributes generic antimalarials, including generic atovaquone/proguanil and other malaria prevention and treatment products. As a generic competitor to ARAKODA's branded positioning, Lupin is the broad incumbent that most directly competes on price in malaria prophylaxis channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks3 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/60-degrees-pharmaceuticals-inc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds8 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 60 Degrees Pharma